Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Overcoming viral escape with vaccines that generate and display antigen diversity in vivo | Virology Journal BioMed Central Open Access Hypothesis Overcoming viral escape with vaccines that generate and display antigen diversity in vivo Albert García-Quintanilla Address Atanasio Barrón 14 P4-5A 41003 Sevilla Spain Email Albert García-Quintanilla - albertgq1970@ Published 22 November 2007 Received 4 October 2007 Accepted 22 November 2007 Virology Journal 2007 4 125 doi 1743-422X-4-125 This article is available from http content 4 1 125 2007 García-Quintanilla licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Viral diversity is a key problem for the design of effective and universal vaccines. Virtually a vaccine candidate including most of the diversity for a given epitope would force the virus to create escape mutants above the viability threshold or with a high fitness cost. Presentation of the hypothesis Therefore I hypothesize that priming the immune system with polyvalent vaccines where each single vehicle generates and displays multiple antigen variants in vivo will elicit a broad and long-lasting immune response able to avoid viral escape. Testing the hypothesis To this purpose I propose the use of yeasts that carry virus-like particles designed to pack the antigen-coding RNA inside and replicate it via RNA-dependent RNA polymerase. This would produce diversity in vivo limited to the target of interest and without killing the vaccine vehicle. Implications of the hypothesis This approach is in contrast with peptide cocktails synthesized in vitro and polyvalent strategies where every cell or vector displays a single or definite number of mutants but similarly to all them it should be able to overcome original antigenic sin avoid major histocompatibility .
